We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MetLife (MET) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
In its upcoming report, MetLife (MET - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.36 per share, reflecting an increase of 13.5% compared to the same period last year. Revenues are forecasted to be $25.57 billion, representing a year-over-year increase of 29.6%.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific MetLife metrics that are commonly monitored and projected by Wall Street analysts.
Analysts predict that the 'Revenue- Net investment income' will reach $5.50 billion. The estimate suggests a change of +1.7% year over year.
The collective assessment of analysts points to an estimated 'Revenue- Other Revenues' of $661.92 million. The estimate indicates a year-over-year change of +3.3%.
The average prediction of analysts places 'Revenue- Universal life and investment-type product policy fees' at $1.26 billion. The estimate indicates a year-over-year change of +3.4%.
It is projected by analysts that the 'Adjusted Revenue- Group Benefits- Other Revenues' will reach $404.67 million. The estimate points to a change of +7.1% from the year-ago quarter.
Analysts forecast 'Total Adjusted Revenue- EMEA' to reach $782.70 million. The estimate indicates a year-over-year change of +10.1%.
The consensus estimate for 'Adjusted Revenue- Asia- Universal life and investment-type product policy fees' stands at $398.66 million. The estimate points to a change of -2.8% from the year-ago quarter.
Analysts' assessment points toward 'Adjusted Revenue- Latin America- Universal life and investment-type product policy fees' reaching $367.09 million. The estimate indicates a change of +11.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Adjusted Revenue- EMEA- Universal life and investment-type product policy fees' should come in at $82.90 million. The estimate suggests a change of +9.1% year over year.
Analysts expect 'Total Adjusted Revenue- Asia' to come in at $3.03 billion. The estimate points to a change of +5.1% from the year-ago quarter.
The combined assessment of analysts suggests that 'Adjusted Revenue- Asia- Net investment income' will likely reach $1.38 billion. The estimate indicates a year-over-year change of +10.5%.
Based on the collective assessment of analysts, 'Adjusted Revenue- EMEA- Net investment income' should arrive at $63.95 million. The estimate points to a change of +8.4% from the year-ago quarter.
The consensus among analysts is that 'Adjusted Revenue- Latin America- Net investment income' will reach $428.82 million. The estimate indicates a change of -0.5% from the prior-year quarter.
MetLife shares have witnessed a change of -0.9% in the past month, in contrast to the Zacks S&P 500 composite's +0.9% move. With a Zacks Rank #4 (Sell), MET is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MetLife (MET) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
In its upcoming report, MetLife (MET - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.36 per share, reflecting an increase of 13.5% compared to the same period last year. Revenues are forecasted to be $25.57 billion, representing a year-over-year increase of 29.6%.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific MetLife metrics that are commonly monitored and projected by Wall Street analysts.
Analysts predict that the 'Revenue- Net investment income' will reach $5.50 billion. The estimate suggests a change of +1.7% year over year.
The collective assessment of analysts points to an estimated 'Revenue- Other Revenues' of $661.92 million. The estimate indicates a year-over-year change of +3.3%.
The average prediction of analysts places 'Revenue- Universal life and investment-type product policy fees' at $1.26 billion. The estimate indicates a year-over-year change of +3.4%.
It is projected by analysts that the 'Adjusted Revenue- Group Benefits- Other Revenues' will reach $404.67 million. The estimate points to a change of +7.1% from the year-ago quarter.
Analysts forecast 'Total Adjusted Revenue- EMEA' to reach $782.70 million. The estimate indicates a year-over-year change of +10.1%.
The consensus estimate for 'Adjusted Revenue- Asia- Universal life and investment-type product policy fees' stands at $398.66 million. The estimate points to a change of -2.8% from the year-ago quarter.
Analysts' assessment points toward 'Adjusted Revenue- Latin America- Universal life and investment-type product policy fees' reaching $367.09 million. The estimate indicates a change of +11.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Adjusted Revenue- EMEA- Universal life and investment-type product policy fees' should come in at $82.90 million. The estimate suggests a change of +9.1% year over year.
Analysts expect 'Total Adjusted Revenue- Asia' to come in at $3.03 billion. The estimate points to a change of +5.1% from the year-ago quarter.
The combined assessment of analysts suggests that 'Adjusted Revenue- Asia- Net investment income' will likely reach $1.38 billion. The estimate indicates a year-over-year change of +10.5%.
Based on the collective assessment of analysts, 'Adjusted Revenue- EMEA- Net investment income' should arrive at $63.95 million. The estimate points to a change of +8.4% from the year-ago quarter.
The consensus among analysts is that 'Adjusted Revenue- Latin America- Net investment income' will reach $428.82 million. The estimate indicates a change of -0.5% from the prior-year quarter.
View all Key Company Metrics for MetLife here>>>MetLife shares have witnessed a change of -0.9% in the past month, in contrast to the Zacks S&P 500 composite's +0.9% move. With a Zacks Rank #4 (Sell), MET is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .